SuperworthAnnovis Bio EPS ANVS
Diluted earnings per share by quarter and over the last twelve months, from 2019.
- Last 12 months, to Jun 30, 2026
- −$1.79
- Latest quarter, Q2 FY26
- −$0.40
- Fiscal year 2025
- −$1.40
Annovis Bio's earnings per share was −$1.79 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.40.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.40 | n/a |
| FY2024 | −$2.53 | n/a |
| FY2023 | −$6.13 | n/a |
| FY2022 | −$3.11 | n/a |
| FY2021 | −$1.88 | n/a |
| FY2020 | −$0.84 | n/a |
| FY2019 | −$3.51 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.40 | n/a | −$1.79 | |
| Q1 FY26 | −$0.63 | n/a | −$1.71 | |
| Q4 FY25 | −$0.39 | n/a | −$1.40 | |
| Q3 FY25 | −$0.37 | n/a | −$1.41 | |
| Q2 FY25 | −$0.32 | n/a | −$2.01 | |
| Q1 FY25 | −$0.32 | n/a | −$2.13 | |
| Q4 FY24 | −$0.40 | n/a | −$2.53 | |
| Q3 FY24 | −$0.97 | n/a | −$4.37 | |
| Q2 FY24 | −$0.44 | n/a | −$5.03 | |
| Q1 FY24 | −$0.72 | n/a | −$5.66 | |
| Q4 FY23 | −$2.24 | n/a | −$6.13 | |
| Q3 FY23 | −$1.63 | n/a | −$4.84 |
Against its peers
Companies in Drug Manufacturers - General nearest Annovis Bio's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ANVSAnnovis Bio | −$1.79 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Annovis Bio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.